Literature DB >> 2140681

Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients.

R W Hoffman1, L J Rettenmaier, Y Takeda, J E Hewett, I Pettersson, U Nyman, A M Luger, G C Sharp.   

Abstract

Serum samples from patients with connective tissue disease (CTD) were characterized using a recently developed enzyme-linked immunosorbent assay for reactivity with individual specific polypeptides of U1 small nuclear ribonucleoproteins, including the U1-70-kd protein. The distribution of HLA antigens was compared in CTD patients with and in those without anti-U1-70-kd autoantibodies and in normal controls. The frequencies of HLA-DR4 and HLA-DRw53 were increased among the anti-U1-70-kd autoantibody positive CTD group compared with the frequencies in anti-U1-70-kd autoantibody negative systemic lupus erythematosus patients and compared with normal controls. We conclude that the presence of autoantibodies reactive with the anti-U1-70-kd protein antigen is associated with HLA-DR4 and HLA-DRw53.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2140681     DOI: 10.1002/art.1780330509

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Blotting patterns of IgG anti-(U1)RNP antibodies in mixed connective tissue disease.

Authors:  A Ghirardello; A Doria; P Vesco; E Vaccaro; C Bernardi; C Catani; U Fagiolo; P F Gambari
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

3.  T cell lines recognizing the 70-kD protein of U1 small nuclear ribonucleoprotein (U1snRNP).

Authors:  S Fenning; G Wolff-Vorbeck; W Hackl; U Krawinkel; R Lührmann; W Northemann; H H Peter; M Schlesier
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

Review 4.  Genetics and proteomics in scleroderma.

Authors:  Carol A Feghali-Bostwick
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

5.  Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy.

Authors:  YunJuan Zang; Laisel Martinez; Irina Fernandez; Judith Pignac-Kobinger; Eric L Greidinger
Journal:  J Immunol       Date:  2014-03-26       Impact factor: 5.422

6.  Antiphospholipid syndrome plus rheumatic fever: a higher risk factor for stroke?

Authors:  Elisa Watanabe Camargo; Paula Vieira Freire; Clovis Artur Silva; Nelita Rocha dos Santos; Licia Maria Henrique da Mota; Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

7.  HLA class II genes and antibodies against recombinant U1-nRNP proteins in patients with systemic lupus erythematosus. SLE Study Group.

Authors:  Z Yao; H P Seelig; H Ehrfeld; M Renz; K Hartung; H Deicher; E Keller; C Nevinny-Stickel; E D Albert
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

8.  IgG and IgM anti-snRNP reactivity in sequentially obtained serum samples from patients with connective tissue diseases.

Authors:  U Nyman; I Lundberg; E Hedfors; M Wahren; I Pettersson
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

9.  Characterization of an HLA-DR4-restricted T cell clone recognizing a protein moiety of small nuclear ribonucleoproteins (UsnRNP).

Authors:  G Wolff-Vorbeck; W Hackl; S Fenning; U Krawinkel; R Lührmann; H H Peter; M Schlesier
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

10.  Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population.

Authors:  Marcos E Maldonado; Magdalena Perez; Judith Pignac-Kobinger; Emily Triana Marx; Elaine M Tozman; Eric L Greidinger; Robert W Hoffman
Journal:  J Rheumatol       Date:  2008-02-01       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.